Brain Health Supplements Manufacturer

Two quotes are the same SKU only when these fields match. An unnamed “brain complex” weight is not a quote.

Also name format, serving architecture, pack, destination, and the finished-unit tests wanted on release. PS + DHA or ginkgo + DHA usually split dry capsule and oil softgel.

If the formula is not locked yet. Destination, architecture, active, milligram band, and format.— Request Formula Feasibility.
If a BOM already exists. Actives, milligram or marker band, format, pack, and destination.— Send Your BOM.
If the job is a finished SKU match. Current specification, BOM, COA set, pack drawing, and quality questionnaire. — Request a Second-Source Review.

After the file arrives, missing or conflicting fields are named, format and fill are checked, then the sample plan, MOQ, and quotation. A complete brief is not required to start — send the label, destination, and the supplier file on hand.

Testing is included when specified in the approved product specification or quality agreement. Finished-product release is tested against that file.

Incoming. Identity, assay / marker with the method on the same line, microbiology, heavy metals. PS: HPLC plus soy allergen when the lecithin is soy. Ginkgo: flavone / terpene pair and ginkgolic acids when specified. DHA: fatty-acid profile plus PV / p-AV / TOTOX; fish allergen when the oil is marine. Supplier COA is checked against the approved specification. Customer-supplied drums follow the same incoming checks.
In-process. Blend uniformity, fill or tablet weight variation, moisture on dry fills; oxygen and temperature control on oil fills.
Finished product. Printed assay for each labeled row; PV / p-AV / TOTOX on oil SKUs; micro; metals; pack integrity. After a gummy cook, assay is done on the piece. Delayed-release softgels carry the named opening test when that route is on the file.
File. Specification, finished-product COA, test records, batch genealogy, allergen statement, stability documentation when specified. In-house HPLC / GC plus SGS or Eurofins when the quality agreement names them. See Quality Control and How to Read a COA.

Change control. A qualified alternate raw material is not an automatic swap. Where a change can move assay, allergen, oxidation profile, marker profile, or a label declaration, it is reviewed against the approved specification before use.
Supply continuity. Production is planned against qualified sources and the approved specification. An alternate source is used only after qualification and change-control review. Unapproved raw-material substitution is not a dual-source method.
Repeatability. Repeat production follows the approved master specification, qualified raw-material sources, and release test plan unless a documented change-control review is opened.
Nonconformance. Results outside the approved specification go on hold for investigation. The batch is released only after the deviation is closed under a documented QA procedure, with corrective and preventive action when required. Batch genealogy supports complaint investigation.
Confidentiality and IP. NDA can be put in place before detailed formula exchange. Customer-specific specifications, artwork, and project documents are handled according to the agreed commercial and confidentiality terms.
Audit readiness. Supplier questionnaires, quality agreements, and site-audit requirements can be incorporated into qualification before commercial approval.

(1) Oil oxidation on DHA fills

Challenge
PV and p-AV can move between the incoming drum and the released softgel. Two quotes that both say “DHA 200 mg” are not the same SKU if source and TOTOX differ.

Our manufacturing approach
Lock algal vs fish, TG vs EE, and the oxidation panel before sampling. Nitrogen handling, antioxidant strategy, and light-and-oxygen barrier pack sit on that file. Finished-product TOTOX is a release field, not only an incoming drum number.

(2) Dry phospholipid plus oil DHA in one unit

Challenge
A powder PS grade and a liquid DHA fill do not share one two-piece capsule without a dedicated oil-powder or dual-chamber file. Forcing both into one softgel without an oil-compatible PS system fails on fill, leak, or assay.

Our manufacturing approach
Default is a split SKU: PS or ginkgo in a capsule, DHA in a softgel. Dry PS + oil DHA requires a separate feasibility review before the line is booked.

(3) PS concentrate loading

Challenge
Headline PS milligrams hide fill weight. A 20% grade and a 50% or 70% grade at the same printed milligram are different capsule counts. Soy vs sunflower changes allergen labeling.

Our manufacturing approach
Fill, unit count, and pack follow the concentrate. Assay, source, and grade sit on one RFQ line.

(4) Ginkgo 24/6 vs powder vs ratio extract

Challenge
“Ginkgo 120 mg” can be leaf powder, a ratio extract, or a 24/6 standardized extract.

Our manufacturing approach
Leaf identity, flavone / terpene pair, HPLC, and the ginkgolic-acid limit (if required) are locked before quotation. A tighter customer cap is written on the specification; it is not assumed to be a statutory limit.

Packaging is selected against oxidation, light, moisture, and leak — not only the shelf photo.

DHA / astaxanthin / perilla oil. Opaque or amber pack, induction seal, oxygen absorber or nitrogen when specified.
PS powder. HDPE / PET plus desiccant; alu-alu or blister for humid lanes.
Ginkgo extract. Bottle plus desiccant; blister when the lane is humid.
Powder / stick. Barrier film is part of the oil-powder specification.

Shelf-life is assigned from the approved stability program and packaging configuration; it is not inferred from the raw-material shelf life.

Finished-SKU MOQ is quoted after formula, dosage form, serving size, and packaging are confirmed.
Pilot MOQ covers the line and pack freeze before the commercial batch.
Bulk-ingredient MOQ is a separate kilogram RFQ.

Vegetarian shells and delayed-release routes usually raise the practical start versus a standard gelatin oil. Softgel, gummy, powder, and liquid timing is confirmed after the format and pilot requirements are locked.

Once specification, packaging, and process parameters are approved, repeat production uses the same master specification and release test plan. Capacity and scheduling are confirmed against the SKU, order volume, and required testing window.

What determines the quote. Active assay and concentration; source and any licensed grade; milligrams per serving; dosage form; capsule or shell specification; packaging; testing panel; order volume; destination-specific documentation. The same printed milligram does not necessarily mean the same manufacturing cost.

Development work sits with the R&D Center.

Destination review. We review the brief against destination ingredient restrictions and issue specification and batch files. U.S. dietary-supplement, Canadian NHP, EU food-supplement / member-state, and Australian therapeutic-goods pathways can differ on botanicals, phospholipid source claims, and fish vs algal oil labeling. Name the destination before milligrams and artwork freeze. Some concentrated ingredients, extraction processes, or specific forms may require a Novel Food assessment in the EU — the exact ingredient, source, process, and intended use should be checked before launch. A U.S. 24/6 capsule is not an EU-wide traditional-herbal file. Halal-facing briefs lock shell and oil on the same line: Halal gelatin is not vegetarian, and algal DHA is a different source file from fish oil.

Label and claims. Brand-owner counsel owns the finished label, including ginkgo anticoagulant / pre-surgery language where the market requires it. Print structure/function language after destination counsel signs off. This is manufacturing and specification support, not a legal opinion or product registration.

Named specifications. Cognizin®, Sharp-PS® and similar licensed grades require customer authorization. NSF, USP, and oil-supplier IFOS certificates are arranged when the RFQ names them — they are not KS factory marks. Organic programs, apoaequorin SKUs, and coffee-fruit / coffee-cherry extracts are outside this line.

For brain health supplement projects, supplier selection depends on more than dosage-form capability. KS supports specification matching, raw-material control, testing, change control, documentation, and repeat production — for private-label, custom, existing-file, and transfer briefs.

The question is not whether a formula can be made once. It is whether the specification, testing, packaging controls, change-control terms, and repeat-production plan can be documented and maintained.

Certifications · Quality Control · Manufacturing Capacity · About Us

Can you manufacture our existing SKU as a second source?
Yes as OEM against the approved specification, after supplier qualification. Send the current specification, BOM, label, finished-product COA, incoming COAs, pack drawing, test list, and quality questionnaire. The review names which fields must stay equivalent and which need re-validation. Sample, customer approval, and pilot sit before the master specification is frozen. Silent substitution of sunflower for soy, or algal oil for fish oil, is a new file.

What information do you need for a second-source review?
The approved specification, BOM, current COA set, pack drawing, finished-product test list, quality questionnaire, and target volume. If the file is incomplete, send the label, destination, and whatever supplier documents you have — missing fields are listed before quotation. NDA available before detailed formula exchange.

Can PS and DHA be combined in one product?
As a split SKU by default: dry PS or ginkgo in a capsule, DHA in a softgel. A two-piece hard capsule does not hold a bulk oil fill without an oil-powder file. One-unit combinations are a dual-chamber or oil-dispersible review, not a blend-weight rename.

What documents can we receive with the finished product?
Release includes the finished-product COA against the approved specification. Incoming supplier COA is checked at qualification; it is not the only finished-product document. Oil SKUs carry PV, p-AV, and TOTOX when that panel is on the file. Microbiology, heavy metals, allergen statement, pack integrity, batch records, and — when specified — SGS or Eurofins reports and stability documentation.

What is the MOQ and lead time?
Finished-SKU MOQ is quoted after formula, dosage form, serving size, and packaging are confirmed. Planning bands: capsules about 3,000–5,000 units/SKU; tablets about 5,000–10,000 units. Softgel MOQ depends on fill, shell, tooling, oil source, and pack. Gummies, powders, and liquids follow the format file. Capsule sample often 7–15 days after spec lock; mass production often 30–45 days after formula, artwork, pack, and schedule. Softgel, gummy, powder, and liquid timing is confirmed after the format and pilot requirements are locked.